Ipca Laboratories Limited
IPCALAB
Rang in aandelen
#3414
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Aandeelprijs
$20.00
Marktkapitalisatie
$5.08B
Verandering (1 dag)
-1.76%
Verandering (1 jaar)
36.89%
Land
IN
Handel Ipca Laboratories Limited (IPCALAB)
Categorie
Healthcare
EPS voor Ipca Laboratories Limited (IPCALAB)
EPS per June 2026 TTM: $0.57
Volgens de laatste financiële rapporten en de aandelenkoers van Ipca Laboratories Limited is de huidige EPS van het bedrijf (TTM) $0.57. Eind 2024 had het bedrijf een EPS van $0.26, een stijging ten opzichte van de EPS van 2023 die $0.23 bedroeg.
EPS-geschiedenis van Ipca Laboratories Limited van 2005 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.57 | 67.59% |
| 2025 | $0.34 | 31.43% |
| 2024 | $0.26 | 14.42% |
| 2023 | $0.23 | -50.75% |
| 2022 | $0.46 | -25.34% |
| 2021 | $0.61 | 93.12% |
| 2020 | $0.32 | 25.55% |
| 2019 | $0.25 | 73.94% |
| 2018 | $0.15 | 22.62% |
| 2017 | $0.12 | 113.46% |
| 2016 | $0.06 | -65.49% |
| 2015 | $0.16 | -48.97% |
| 2014 | $0.32 | 34.08% |
| 2013 | $0.24 | 8.86% |
| 2012 | $0.22 | -7.87% |
| 2011 | $0.24 | 28.52% |
| 2010 | $0.18 | 131.65% |
| 2009 | $0.08 | -41.78% |
| 2008 | $0.14 | 16.48% |
| 2007 | $0.12 | 111.05% |
| 2006 | $0.06 | -18.58% |
| 2005 | $0.07 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -2.37% |
IN
|
